The global organoids market size was valued at USD 1.23 billion in 2025 and is projected to grow from USD 1.45 billion in 2026 to USD 5.52 billion by 2034, registering a CAGR of 18.15% during the forecast period (2026–2034). North America dominated the organoids market with a market share of 41.2% in 2025.
Organoids are miniature, three-dimensional models of organs grown from stem cells or tissue cells to study organ functions, diseases, and drug responses. The organoids is generally classified under HSN Code 300290 (other human or animal substances prepared for therapeutic or prophylactic uses, and certain biological products) and SIC Code 8731 (commercial physical and biological research).
Download a Free Sample To learn more about this report,
AI-Based Organoid Image Analysis
The organoids market analysis shows that the complexity of three-dimensional organoid structures creates demand for accurate and automated image analysis in biomedical research. Artificial intelligence and deep learning enable researchers to assess organoid morphology, cellular changes, and drug responses. For instance, a 2025 study introduced the CLORG deep learning framework, which achieved classification accuracies of 91.68% for colon organoids and 86.93% for intestinal organoids, demonstrating the potential of AI-assisted organoid analysis.
Multi-Organoid Assembloid Systems
The need to understand interactions between different human tissues encourages researchers to develop multi-organoid assembloid systems. These systems combine organoids representing different tissue regions, allowing scientists to examine cellular communication, disease mechanisms, and developmental processes more accurately. For instance, Stanford University researchers used more than 1,000 forebrain assembloids in CRISPR-based screening to identify 33 candidate genes associated with abnormal neuronal migration.
Pharmaceutical Investment in Precision Medicine and Wider Availability of Commercial Organoid Culture Kits Drive Market
Pharmaceutical investment in precision medicine increases demand for patient-derived organoids that support individualized drug development and treatment selection. These models preserve important genetic and biological characteristics of patient tumors, allowing researchers to evaluate responses to different therapies. Pharmaceutical companies use organoid-based testing to identify promising drug candidates and improve preclinical decision-making.
The availability of commercial organoid culture kits improves access to standardized three-dimensional cell culture systems across research laboratories. Ready-to-use media, growth factors, and extracellular matrices reduce preparation complexity and support more consistent organoid development. Life science suppliers expand their product portfolios to meet demand from pharmaceutical companies, academic institutions, and biotechnology laboratories. For instance, STEMCELL Technologies offers IntestiCult organoid growth media for the cultivation and maintenance of intestinal organoids in research applications.
Lack of Standardized Protocols and Clinical Validation Restrain Market Expansion
The absence of standardized organoid production protocols creates inconsistencies in organoid quality, structure, and experimental performance across laboratories. Differences in stem cell sources, culture media, and cultivation methods produce variable results, making it difficult for pharmaceutical companies to compare drug responses reliably.
Limited clinical validation restricts the adoption of organoid-based testing in routine healthcare and personalized treatment decisions. Insufficient large-scale clinical studies and inconsistent evidence of treatment prediction accuracy make hospitals and healthcare providers hesitant to integrate these tests into clinical workflows.
CRISPR-Engineered Organoid Models and Organoid-Based Regenerative Medicine Offers Growth Opportunities
Gene-editing companies and biotechnology firms can develop customized organoid models to help pharmaceutical companies identify disease-related genes and potential drug targets. These services create revenue opportunities through genetic screening, model licensing, and research partnerships. For instance, in August 2026, the Broad Institute reported 147 genome-scale CRISPR screens across 10 cancer types using advanced three-dimensional models, demonstrating their value in drug target discovery.
Regenerative medicine companies and tissue engineering firms can explore organoid transplantation to repair damaged tissues, creating future opportunities in cell therapy development and clinical partnerships. For instance, a 2026 peer-reviewed study reported an 82% organoid establishment rate using a clinical-grade culture protocol involving samples from 60 patients, supporting further development of intestinal regenerative therapies.
The neural organoids segment accounted for the largest market share of 31.7%, owing to their application in neurological disease research and brain development studies.
The hepatic organoids segment is expected to grow at a CAGR of 22.7% during the forecast period, driven by their use in liver disease modelling and drug metabolism studies.
Request Customizationto receive a tailored report.
The general submerged method for organoid culture held the largest market share of 28.4%, supported by its established use in organoid cultivation and controlled laboratory environments.
The brain and retina organoid formation protocol segment is projected to grow at a CAGR of 26.1% during the forecast period, fueled by advances in neurological research and specialized organoid model development.
The primary tissues segment dominated the source category with a share of 38.6%, reflecting their relevance in preserving native tissue characteristics for biological studies.
The induced pluripotent stem cells (iPSCs) segment is anticipated to register a CAGR of 27.3% during the forecast period, driven by their potential to generate patient-specific models for disease research and personalized medicine.
The drug toxicity and efficacy testing segment accounted for the largest market share of 23%, owing to the use of organoids in evaluating drug responses and potential toxic effects.
The personalized medicine segment is expected to grow at a CAGR of 25.9% during the forecast period, driven by demand for patient-specific disease models and tailored treatment evaluation.
The pharmaceutical and biotechnology companies segment held the largest market share of 42.3%, supported by investments in drug discovery, preclinical testing, and advanced research models.
The hospitals and diagnostic labs segment is projected to grow at a CAGR of 23.2% during the forecast period, fueled by the potential use of organoids in disease modelling and translational research.
Speak to an Analystto discuss market opportunities.
The North America organoids market accounted for the largest regional share of 41.2% in 2025.
The U.S. National Institutes of Health (NIH) has proposed USD 25 million for fiscal year 2027 to support new approach methodologies as alternatives to animal models. This initiative potentially expands opportunities for organoid-based drug testing and biomedical research.
Canada's Stem Cell Network offers up to CAD 270,000 per early-career research project and CAD 290,000 per proof-of-principle project under its 2026 funding competition. This funding potentially strengthens the development of organoid culture technologies and disease modeling applications during 2027–2028.
Unlock Regional Insightsto access country-level data, & regional trends.
The Europe organoids market is expected to grow at the fastest CAGR of 22.1% during the forecast period.
UK Research and Innovation plans to invest GBP 3.7 billion in discovery and curiosity-driven research during 2026–2027, including life sciences research. This investment potentially creates broader funding opportunities for organoid-based disease modeling and regenerative medicine technologies.
Germany's Federal Ministry of Research, Technology and Space (BMFTR) is funding the Technical University of Munich's SYMPHOGUT project with EUR 1.93 million from July 2026 through June 2031. This funding supports advanced intestinal organoid platforms for inflammatory bowel disease research and personalized drug development.
The Asia Pacific organoids market is anticipated to record a growth rate of 25.8% during the forecast period.
China's National Natural Science Foundation (NSFC) also plans to support 8–10 major research projects with approximately CNY 2.8 million each during 2027–2030, including research involving organoid and embryo-like models. This funding potentially strengthens advanced organoid development and biomedical innovation.
Japan's AMED regenerative medicine innovation program provides approximately JPY 15–25 million annually per project for up to three years. This funding potentially supports future organoid research, stem cell technologies, and regenerative medicine applications.
India's Department of Health Research received a fiscal 2026–2027 budget allocation of INR 4,821.21 crore, approximately 24% higher than the previous year's revised estimates. This allocation potentially supports advanced biomedical research and the development of human-relevant organoid testing technologies.
The global organoids market is moderately fragmented, with a mix of established biotechnology companies, specialized organoid developers, and emerging startups competing across different applications. Key players such as Corning Incorporated, Danaher Corporation (Molecular Devices), Hubrecht Organoid Technology (HUB), and InSphero are estimated to account over 10–15% of organoids market share.
Established players focus on extensive product portfolios, standardized organoid culture systems, and strategic collaborations. Emerging players in the organoids market ecosystem primarily compete through technological innovation, disease-specific organoid models, and specialized applications in drug discovery and regenerative medicine.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Sample Preparation Market Size, Forecast, Opportunities, 2034
Cell Harvesting Systems Market Size, Forecast, Demand, Opportunities, 2034
Cell Culture Market Size, Share, Growth, Analysis, Report, 2034
Antisense Oligonucleotides Market Size, Forecast, Demand, Opportunities, 2034
Automated Sample Storage Systems Market Size, Forecast, Opportunities, 2034
Biosensors Market Size, Share, Growth, Analysis, Report, 2034
We are featured on:
sales@straitsresearch.com